MDXG Healthcare

MiMedx Group, Inc.

$3.25-0.91%

Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 474.3M USD
Enterprise value: 527.1M USD
Full-time employees: 808

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its share price swings more than most peers’ (beta 1.17 vs a peer median of 0.63)bigger price swings (beta 1.17 vs peers 0.63)
About average: profitability, valuation and risk (debt, liquidity and share-price swings)profitability, valuation and risk

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 28% from December 2022 to July 2026.
MiMedx had 28% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.MiMedx had 28% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock pay outran buybacks. Stock-based pay expense $50M vs $10M spent repurchasing shares over the 3 fiscal years to 2025.
Over three fiscal years MiMedx recorded $50M of stock-based pay expense and spent $10M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years MiMedx recorded $50M of stock-based pay expense and spent $10M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.
Cash flow well above reported profit. Free cash flow is 7.1× reported profit.
Free cash flow is 7.1× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Revenue is falling. Revenue fell 2.4% in the 12 months to June 2026 vs the 12 months before.
MiMedx's revenue fell 2.4% in the 12 months to June 2026 vs the 12 months before.

StockQuotient Score

46/ 100▲ 1 since Oct 27 close

Oct 5 43 → Nov 4 46 (+3)

Valuation

Is the price right?

54/100

Moderate▲ 4 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Share count down 2.1%

Valuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 50 → 54

Share price -16.7%+4
Company's reported figures updated+1
Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Helped by:

▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield1.3%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score -0.11Sector median: 0.0148 · MAD: 0.0148

EBITDA yield6.7%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.66Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield9.4%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield45.6%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

18/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 8.8%

Why

Weaker than most peers on:

▼ EPS growth
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth-80.3%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -2.79Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth6.4%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.06Sector median: 0.0584 · MAD: 0.0840

Revenue growth-2.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

49/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 7.7 points to 2.5%

Why

Held back by:

▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin2.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.38Sector median: 0.0706 · MAD: 0.1217

Return on assets2.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.10Sector median: 0.0166 · MAD: 0.0537

Return on invested capital7.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.24Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin78.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity2.9%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 64 → 63

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Mixed versus peers:

▲ Current ratio
▲ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.17

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.62Sector median: 0.6250 · MAD: 0.3380

Current ratio5.33×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.98Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.08×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.70Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about MiMedx

Is MiMedx getting weaker?: Its latest SEC filing (Jul 29, 2026) was mixed: some things better, some worse: operating margin fell 7.7 points to 2.5%; 12-month revenue fell 8.8%. Its overall score is 46/100, up 1 since Oct 28, 2026.
How is MiMedx valued vs its peers?: Priced about in line with its peers. Valuation scores 54/100 against 1,393 healthcare peers. EBITDA yield 6.7% vs a peer median of 4.0% (stronger than 67% of peers).EBITDA yield 6.7% vs peers 4.0% (stronger than 67% of peers).
Is MiMedx growing?: More slowly than most of its peers. Growth scores 18/100 against 1,393 healthcare peers. Earnings per share growth -80.3% vs a peer median of 9.8% (weaker than 100% of peers).Earnings per share growth -80.3% vs peers 9.8% (weaker than 100% of peers).
How profitable is MiMedx?: About as profitable as its peers. Profitability scores 49/100 against 1,393 healthcare peers. Operating margin 2.5% vs a peer median of 7.1% (weaker than 62% of peers).Operating margin 2.5% vs peers 7.1% (weaker than 62% of peers).
How risky is MiMedx?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.33× vs a peer median of 2.59× (stronger than 75% of peers).Current ratio 5.33× vs peers 2.59× (stronger than 75% of peers). Beta 1.17 vs a peer median of 0.63 (weaker than 79% of peers).Beta 1.17 vs peers 0.63 (weaker than 79% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 29, 2026 · compared with the quarter ended Mar 31, 2026

Mixed: some things better, some worse

Operating margin fell 7.7 points to 2.5%
12-month revenue fell 8.8%
Share count down 2.1%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	389.4M USD	355.2M USD	−8.8%
Net income (12 months)	30.7M USD	6.2M USD	−79.7%
Operating margin	10.2%	2.5%	−7.7 pts
Debt	17.6M USD	17.2M USD	−2.2%
Cash	159.8M USD	135.8M USD	−15.0%
Shares outstanding	148.9M	145.8M	−2.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	83.6%	82.0%	83.0%	82.8%	82.6%	▼ 0.2 pts
Operating margin	-2.9%	-5.5%	11.5%	16.9%	15.3%	▼ 1.6 pts
Net margin	-4.2%	-11.3%	18.1%	12.2%	11.6%	▼ 0.6 pts
Return on assets (ROA)	-5.5%	-17.6%	24.4%	16.1%	14.2%	▼ 1.9 pts
Return on equity (ROE)	—	—	40.8%	22.0%	18.9%	▼ 3.0 pts
Free cash flow margin	-2.1%	-7.2%	7.7%	—	—	—
Current ratio	3.51×	3.08×	3.57×	4.21×	4.32×	▲ 2.6%
Quick ratio	3.24×	2.78×	3.11×	3.69×	3.92×	▲ 6.4%
Debt to equity	—	—	0.35×	0.10×	0.07×	▼ 29%
Interest coverage	—	-2.92×	5.65×	14.95×	35.83×	▲ 140%

MDXG price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its share price swings more than most peers’ (beta 1.17 vs a peer median of 0.63)bigger price swings (beta 1.17 vs peers 0.63)

About average: profitability, valuation and risk (debt, liquidity and share-price swings)profitability, valuation and risk

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 28% from December 2022 to July 2026.

MiMedx had 28% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.MiMedx had 28% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock pay outran buybacks. Stock-based pay expense $50M vs $10M spent repurchasing shares over the 3 fiscal years to 2025.

Over three fiscal years MiMedx recorded $50M of stock-based pay expense and spent $10M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years MiMedx recorded $50M of stock-based pay expense and spent $10M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.

Cash flow well above reported profit. Free cash flow is 7.1× reported profit.

Free cash flow is 7.1× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.

Revenue is falling. Revenue fell 2.4% in the 12 months to June 2026 vs the 12 months before.

MiMedx's revenue fell 2.4% in the 12 months to June 2026 vs the 12 months before.

Questions investors ask about MiMedx

Is MiMedx getting weaker?

Its latest SEC filing (Jul 29, 2026) was mixed: some things better, some worse: operating margin fell 7.7 points to 2.5%; 12-month revenue fell 8.8%. Its overall score is 46/100, up 1 since Oct 28, 2026.

How is MiMedx valued vs its peers?

Priced about in line with its peers. Valuation scores 54/100 against 1,393 healthcare peers. EBITDA yield 6.7% vs a peer median of 4.0% (stronger than 67% of peers).EBITDA yield 6.7% vs peers 4.0% (stronger than 67% of peers).

Is MiMedx growing?

More slowly than most of its peers. Growth scores 18/100 against 1,393 healthcare peers. Earnings per share growth -80.3% vs a peer median of 9.8% (weaker than 100% of peers).Earnings per share growth -80.3% vs peers 9.8% (weaker than 100% of peers).

How profitable is MiMedx?

About as profitable as its peers. Profitability scores 49/100 against 1,393 healthcare peers. Operating margin 2.5% vs a peer median of 7.1% (weaker than 62% of peers).Operating margin 2.5% vs peers 7.1% (weaker than 62% of peers).

How risky is MiMedx?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.33× vs a peer median of 2.59× (stronger than 75% of peers).Current ratio 5.33× vs peers 2.59× (stronger than 75% of peers). Beta 1.17 vs a peer median of 0.63 (weaker than 79% of peers).Beta 1.17 vs peers 0.63 (weaker than 79% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

389.4M USD

355.2M USD

−8.8%

Net income (12 months)

30.7M USD

6.2M USD

−79.7%

Operating margin

10.2%

2.5%

−7.7 pts

Debt

17.6M USD

17.2M USD

−2.2%

Cash

159.8M USD

135.8M USD

−15.0%

Shares outstanding

148.9M

145.8M

−2.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

83.6%

82.0%

83.0%

82.8%

82.6%

▼ 0.2 pts

Operating margin

-2.9%

-5.5%

11.5%

16.9%

15.3%

▼ 1.6 pts

Net margin

-4.2%

-11.3%

18.1%

12.2%

11.6%

▼ 0.6 pts

Return on assets (ROA)

-5.5%

-17.6%

24.4%

16.1%

14.2%

▼ 1.9 pts

Return on equity (ROE)

—

40.8%

22.0%

18.9%

▼ 3.0 pts

Free cash flow margin

-2.1%

-7.2%

7.7%

—

Current ratio

3.51×

3.08×

3.57×

4.21×

4.32×

▲ 2.6%

Quick ratio

3.24×

2.78×

3.11×

3.69×

3.92×

▲ 6.4%

Debt to equity

—

0.35×

0.10×

0.07×

▼ 29%

Interest coverage

—

-2.92×

5.65×

14.95×

35.83×

▲ 140%